Neurolixis is developing a platform of early-stage drug candidates targeting serious CNS diseases with unmet medical needs and sizeable market opportunity. Compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism" which enables drugs to more precisely target specific brain regions controlling CNS disorders.
NLX-204 is the lead novel chemical entity from the drug discovery program. It is a candidate for development as a potential rapid-acting antidepressant or analgesic (non-opioid mechanism).
All drugs or therapies will be subjected to rigorous testing under applicable law and approval by regulatory authorities, including the FDA, prior to marketing and sale.